Immunomedics, Inc.(NASDAQ : IMMU)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading IMMU News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.01%||70.49||1.0%||$914.02m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.43%||378.85||1.9%||$338.90m|
|ALXN||Alexion Pharmaceuticals, Inc.||1.51%||133.23||2.0%||$303.80m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.42%||91.00||2.6%||$140.36m|
|CLVS||Clovis Oncology, Inc.||2.94%||59.51||16.4%||$119.33m|
|BMRN||BioMarin Pharmaceutical Inc.||0.39%||94.30||3.9%||$109.15m|
|A||Agilent Technologies, Inc.||1.25%||51.94||1.7%||$107.79m|
|ACAD||ACADIA Pharmaceuticals Inc.||-3.42%||36.81||19.0%||$93.80m|
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It markets and sells its products in the U.S. and throughout Europe. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.